Identification of new modulators and protein alterations in non‐apoptotic programmed cell death |
| |
Authors: | Sabina Sperandio Karen S. Poksay Birgit Schilling Danielle Crippen Bradford W. Gibson Dale E. Bredesen |
| |
Affiliation: | 1. Buck Institute for Age Research, Novato, California 94945;2. Center for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;3. Department of Neurology, University of California‐San Francisco, San Francisco, California |
| |
Abstract: | This study describes the first proteomic analysis of paraptosis—a non‐apoptotic form of programmed cell death. As with apoptosis, the first description of paraptosis was based on morphological criteria. Since there are no known markers for paraptosis, the purpose of this study was to dissect changes in the proteome profile occurring during paraptosis. Using one‐ and two‐dimensional SDS–PAGE, Western analysis, and mass spectrometry, we show that during paraptosis, alterations occur mainly in cytoskeletal proteins, signal transduction proteins, mitochondrial proteins, and some metabolic proteins. We also report the identification of: (1) a paraptosis inhibitor, phosphatidylethanolamine binding protein (PEBP‐1), and (2) a candidate mediator of paraptosis, prohibitin. Identification of specific paraptotic changes will ultimately lead to tools to detect this type of programmed cell death in in vivo systems and allow for its further characterization. J. Cell. Biochem. 111: 1401–1412, 2010. © 2010 Wiley‐Liss, Inc. |
| |
Keywords: | paraptosis proteomics insulin‐like growth factor I receptor |
|
|